Research & Clinical Trials
Raffles Cancer Centre actively seeks partnerships with research organisations who share our passion in our mission to provide the best cancer care for our patients.
Clinical trials constitute an integral component of patient management at Raffles Hospital. Through these trials, our patients have access to novel therapeutic agents, which have yet to be made available in the market. These clinical trials give hope to patients whose conditions have failed to respond to standard lines of treatment.
Our oncologists at Raffles Cancer Centre have abundant experience as principal investigators and co-investigators of well over 50 clinical trials in various phases (phase I, II, III), both investigator-initiated and pharmaceutical company-initiated, and as part of larger international multi-centre phase III trials.
Coordinated by the Hospital‘s Clinical Trial Unit, these trials help expand the treatment options available to patients.
All clinical trials involving humans are subjected to approval by the Hospital’s Institutional Review Board (IRB) which ensures all clinical trials are ethically acceptable and that the rights, safety and well-being of the patients are safeguarded at all times. The IRB also monitors the conduct of the clinical trials and ensures that they are in compliance with Good Clinical Practice on an ongoing basis.
| No. | Indication | Study Information | Investigator | Status |
|---|---|---|---|---|
| 1 | Lung Cancer | A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations. (BAYER 22615) | Dr Lee Chern Siang | Recruiting |
| 2 | Lung Cancer | A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non—Small Cell Lung Cancer with KRAS G12C Mutation (Mirati-7 849-007) | Dr Lee Chern Siang | Recruiting |
| 3 | Breast Cancer | Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT) | Dr Lee Chern Siang | Recruiting |
| 4 | Urothelial Cancer | An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater) (Protocol No. SGNDV-001) | Dr Lee Chern Siang | Recruiting |
| 5 | Heat Therapy for malignant tumours | Pilot Study using Remission 1°C Regional Hyperthermia in the Management of Cancer Patients | Dr Brendan Chia | Recruiting |
For more information, please contact:
For more information, please contact:
Raffles Hospital Clinical Trials Unit, Tel: +65 6311 2305Â Mon - Fri (9am - 5pm)
or Email to yang_christie@rafflesmedical.com
Your participation in this research study is purely voluntary. You may withdraw your participation at any phase during the study.
Updated on ​​Jan 2026